Lineage Cell Therapeutics price to book ratio LCTX

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: 4.2×
10-year median: 2.7×
Against its 10-year history: 86th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.6× to 20.1×
Peer median: 5.0×

Lineage Cell Therapeutics' price to book ratio is 4.2× as of Oct 23, 2026.

That is above its ten-year median of 2.7×, higher than on 86% of days in the last ten years.

Over that time it ranged from 0.6× in Dec 2018 to 20.1× in Feb 2026.

The median for 4 biotech stocks of a similar size is 5.0×.

Price to book ratio over time

median 2.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	4.2×	3.9×	20.1×
2025	17.2×	1.2×	19.6×
2024	1.4×	1.4×	4.4×
2023	2.8×	2.3×	3.5×
2022	2.5×	1.8×	3.4×
2021	3.4×	2.8×	4.9×
2020	2.9×	1.0×	2.9×
2019	1.0×	0.7×	2.8×
2018	0.7×	0.6×	3.5×
2017	1.4×	1.4×	3.4×
2016	3.1×	2.8×	28.8×
2015	29.8×	9.1×	32.5×
2014	28.6×	8.7×	28.6×
2013	18.3×	9.6×	23.4×
2012	9.5×	6.1×	10.8×
2011	8.7×	5.6×	8.7×

Against its peers

Companies in Biotechnology nearest Lineage Cell Therapeutics' size, closest first, today.

Company	Price to book ratio
LCTXLineage Cell Therapeutics	4.2×
PLXProtalix BioTherapeutics	2.9×
MGTXMeiraGTx	4.1×
VCELVericel	5.9×
ADMAAdma Biologics	5.9×
Peer median	5.0×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Lineage Cell Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.